GT Biopharma (GTBP) Projected to Post Quarterly Earnings on Tuesday

GT Biopharma (NASDAQ:GTBP) will likely be posting its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect GT Biopharma to post earnings of ($1.55) per share for the quarter.

GT Biopharma Stock Performance

NASDAQ GTBP opened at $2.40 on Tuesday. GT Biopharma has a 52 week low of $1.72 and a 52 week high of $10.66. The stock has a market capitalization of $6.09 million, a P/E ratio of -0.34 and a beta of 0.59. The stock has a fifty day moving average of $2.31 and a 200-day moving average of $2.49.

Analyst Ratings Changes

A number of equities analysts have issued reports on GTBP shares. Roth Mkm started coverage on shares of GT Biopharma in a research note on Monday, December 2nd. They issued a “buy” rating and a $11.00 price objective on the stock. Roth Capital upgraded GT Biopharma to a “strong-buy” rating in a research report on Monday, December 2nd.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.